Index 
 Anterior 
 Seguinte 
 Texto integral 
Processo : 2018/2185(DEC)
Ciclo de vida em sessão
Ciclo relativo ao documento : A8-0135/2019

Textos apresentados :

A8-0135/2019

Debates :

PV 26/03/2019 - 12
CRE 26/03/2019 - 12

Votação :

PV 26/03/2019 - 13.30
Declarações de voto

Textos aprovados :

P8_TA(2019)0271

Debates
Quarta-feira, 27 de Março de 2019 - Estrasburgo Edição revista

11.2. Quitação 2017: Agência Europeia de Medicamentos (EMA) (A8-0135/2019 - Petri Sarvamaa)
Vídeo das intervenções
 

Dichiarazioni di voto orali

 
  
MPphoto
 

  Alex Mayer (S&D). – Mr President, the GBP 500 million bill because the European Medicines Agency (EMA) could not get out of the 25—year lease on a building in Canary Wharf is deeply regrettable. What a waste. And, to my mind, what a waste to lose highly skilled jobs and research capacity from Britain. The EMA is a jewel in the crown, precisely because it attracts businesses and experts. Over the past two decades, it has been invaluable, simplifying and streamlining medicines regulation, allowing companies to get a medicine authorised in every EU country in one go. Alas for Britain, no more.

A medicines manufacturer in my constituency has already set up a new parallel testing facility within the EU to enable it to sell into European Union countries in the future. More cost, meaning less investment in research and development, and for Britain more delays in getting medicines and a rising bill for medicines, and so less money for our NHS – the opposite of what people thought that they were voting for.

 
Última actualização: 28 de Junho de 2019Advertência jurídica